BOSTON, April 25, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2023 financial results at 6:00 am ET on Thursday, May 11, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 11, 2023.
The call can be accessed via teleconference at: Q4 2023 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/wm7hxoqy
A replay of the conference call and webcast will be available for one year beginning on May 11, 2023 at 11:00 am ET using the conference call webcast link provided in this press release.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts:
Olga Guyette, Sr. Director-Investor Relations & Treasury
(781) 356-9763
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Trenk, Manager-Investor Relations
(203) 733-4987
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Josh Gitelson, Director-Global Communications
(781) 356-9776
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$77.24 |
| Daily Change: | 0.06 0.08 |
| Daily Volume: | 80,470 |
| Market Cap: | US$3.880B |
August 15, 2024 August 08, 2024 July 30, 2024 June 18, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
